Covid, Ema starts evaluation of anti-arthritis drug

The European Medicines Agency (EMA) has started the evaluation process for the use of the anti-inflammatory drug tocilizumab in patients suffering from severe covid-19. The drug is being studied for rheumatoid arthritis. The outcome of the EMA assessment is expected by mid-October.